2655 Campus Drive
4 articles with CuraSen
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
CuraSen Therapeutics Expands Management Team; Appoints Peter Butera as Senior Vice President, Operations
CuraSen Therapeutics, Inc., a privately held clinical stage biotechnology company focused on developing therapies to treat neurodegenerative diseases, has appointed Peter Butera as senior vice president, operations
CuraSen Therapeutics Expands Management Team; Industry Veteran and Neuroscience Expert Gabriel Vargas, MD, PhD, Appointed to Chief Medical Officer
CuraSen Therapeutics, Inc. today announced that it has appointed Gabriel Vargas, MD, PhD, as chief medical officer. Dr. Vargas brings to CuraSen more than 12 years of experience in early drug development and neuroscience expertise.
CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases
CuraSen Therapeutics, Inc., a privately held biotechnology company focused on developing therapies to treat neurodegenerative diseases, today announced the closing of a $54.5 million Series A financing.